GlassScriptPhysician profile
Mariam Keramati
NPI 1114217841
$2,321.18
in general payments reported to CMS, 2019-2025
23 companies · $437 in 2025
The $437 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $101 · 2021: $187 · 2022: $384 · 2023: $317 · 2024: $576 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.61 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $641.58 | 2021-2025 | Xeomin |
| Abbvie INC. | $591.36 | 2022-2025 | |
| Allergan, INC. | $229.62 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $147.53 | 2019-2025 | Dysport |
| Merz North America, INC. | $142.96 | 2019-2020 | |
| Biogen, INC. | $133.86 | 2020-2022 | |
| Averitas Pharma INC. | $53.52 | 2023-2024 | Qutenza |
| Microtransponder, INC. | $42.34 | 2024 | |
| Relievant Medsystems, INC. | $37.12 | 2022 | |
| Revance Therapeutics, INC. | $36.98 | 2024 | Daxxify |
| Pacira Pharmaceuticals Incorporated | $27.39 | 2025 | Iovera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.87 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.15 | 2025 | Belbuca |
| Si-Bone, INC. | $23.99 | 2024 | |
| Boston Scientific Corporation | $23.77 | 2024 | Intracept |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $22.08 | 2023 | Sprint Pns System |
| Electronic Waveform Lab, INC. | $21.78 | 2019-2023 | |
| Grt US Holding, INC. | $18.86 | 2022 | |
| Axsome Therapeutics, INC. | $17.26 | 2025 | Symbravo |
| Nalu Medical, INC. | $16.92 | 2024 | Nalu Neurostimulation System |
| Daiichi Sankyo INC. | $16.58 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.50 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Keramati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.